Business Overview: Inogen, Inc. (NASDAQ: INGN)

---

Executive Summary

Inogen, Inc. is a medical technology company focused on respiratory health, developing, manufacturing, and marketing portable and stationary oxygen concentrators along with an expanding set of adjacent respiratory-care products. The company generated $209.8 million in U.S. revenue in 2025, with international sales — made through distributors, resellers, and home medical equipment (HME) providers across roughly 70 countries — contributing about 39.8% of total revenue.

Inogen sells through three channels: direct-to-consumer sales (29.5% of 2025 U.S. revenue), direct-to-consumer rentals billed to Medicare or private insurance (25.4%), and sales to HME providers, distributors, and resellers (45.1%) — giving it a differentiated, diversified go-to-market model relative to pure wholesale respiratory-device makers.

---

1. Core Business Model & How They Work

Inogen's business model centers on selling and renting portable oxygen concentrators directly to patients and through a traditional HME-provider distribution channel simultaneously, supported by Medicare/insurance billing infrastructure for its rental business.

[ Device R&D/manufacturing ] ➡️ [ Direct-to-consumer sales/rentals + HME/distributor/reseller sales ] ➡️ [ Patient use (oxygen therapy, sleep apnea, wound care) ] ➡️ [ Medicare/insurance billing (for rentals) ]

Key Operational Drivers

1. Dual go-to-market model: unlike many medical-device makers that sell solely through HME providers, Inogen also sells and rents directly to consumers, requiring it to maintain national accreditation, state licensure, and Medicare billing capability — infrastructure that is costly and slow for a new entrant to build.
2. Medicare/insurance reimbursement dependency: the direct-to-consumer rental channel and Medicare service reimbursement programs (9.5% of 2025 total revenue) tie a meaningful share of revenue to government and private-payer reimbursement policy.
3. Product-line expansion via partnerships and M&A: Inogen has broadened beyond its core oxygen-concentrator franchise into airway clearance (Simeox, acquired via Physio-Assist in 2023, FDA-cleared December 2024) and CPAP masks (Aurora, launched November 2025 through a Yuwell collaboration).
4. International distribution leverage: selling through distributors, resellers, and HME providers across ~70 countries lets Inogen scale internationally without building a direct sales force in every market.

---

2. Product Portfolio

---

3. Competitive Landscape

• Device manufacturers: Rhythm Healthcare, Caire Medical, Drive DeVilbiss, and others compete on portable/stationary oxygen concentrator hardware. Notably, Philips' Respironics announced in 2024 that it was exiting the U.S. portable concentrator market (though legacy product remains in the field), somewhat reducing one large competitive threat.
• HME/service providers: Lincare, Apria, AdaptHealth, Rotech, and Viemed, plus many local/regional providers, compete on service and features, since Medicare/Medicaid reimbursement largely fixes pricing for the rental/service side of the business.
• Competitive dynamics differ by channel: manufacturers compete mainly on price, quality, financing, features, and service, while providers compete mainly on features and service given reimbursement-set pricing. The filing notes that while some competitors have adopted direct-to-consumer sales, they generally do not offer direct-to-consumer rentals, which require national accreditation, state licensure, and Medicare billing privileges that Inogen has already built.

---

4. Strategic Strengths & Risks

Strengths

• Rare dual-channel model (direct-to-consumer sales/rental plus traditional HME/distributor sales) that few competitors replicate, especially on the direct-to-consumer rental side given regulatory/billing barriers to entry.
• Diversifying product portfolio (Simeox airway clearance, Aurora CPAP masks) reduces reliance on the core oxygen-concentrator category alone.
• International distribution network spanning ~70 countries provides meaningful geographic diversification (39.8% of 2025 revenue from outside the U.S.).
• A major competitor (Philips Respironics) exiting the U.S. portable-concentrator market reduces one source of competitive pressure.

Risks

• Significant reliance on Medicare and private-insurance reimbursement (both direct rental revenue and the 9.5% Medicare service reimbursement share) exposes Inogen to policy and reimbursement-rate risk.
• Highly competitive device market with multiple manufacturers (Rhythm Healthcare, Caire Medical, Drive DeVilbiss) competing partly on price.
• New product lines (Simeox, Aurora) are early-stage and unproven at scale, with execution risk in both regulatory rollout and market adoption.
• HME/provider channel customers (Lincare, Apria, AdaptHealth, Rotech, Viemed) are themselves consolidating, which could shift bargaining power away from device manufacturers like Inogen.

---

5. Financial Overview

---

Summary Conclusion

Inogen's moat comes from a genuinely differentiated dual-channel business model — few competitors can match its direct-to-consumer rental infrastructure, which requires national accreditation, state licensure, and Medicare billing capability built up over years — combined with an expanding respiratory-care product portfolio beyond its core oxygen-concentrator franchise. The biggest forward risk is reimbursement dependency: a meaningful share of Inogen's revenue flows through Medicare and private-insurance billing for rentals and services, so any adverse change in oxygen-therapy reimbursement policy or rates would disproportionately affect the company relative to pure cash-pay device sellers.